Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Indian Journal of Medical and Paediatric Oncology ; 2023.
Article in English | Web of Science | ID: covidwho-20242172


Introduction Children with cancer are immunocompromised due to the disease per se or anticancer therapy. Children are believed to be at a lower risk of severe coronavirus disease 2019 (COVID-19) disease.Objective This study analyzed the outcome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children with cancer.Materials and Methods A retrospective analysis was performed on patients (<= 14 years) with cancer attending the pediatric oncology services of our institute who tested positive for the SARS-CoV-2 infection and those who had COVID-19 disease between August 2020 and May 2021. Real-time reverse transcriptase-polymerase chain reaction performed on the nasopharyngeal swab identified the SARS-CoV-2 infection. The primary endpoints were clinical recovery, interruption of cancer treatment, and associated morbidity and mortality.Results Sixty-six (5.7%) of 1,146 tests were positive for the SARS-CoV-2 infection. Fifty-two (79%) and 14 (21%) patients had hematolymphoid and solid malignancies. Thirty-two (48.5%) patients were asymptomatic. A mild-moderate, severe, or critical disease was observed in 75% (18/24), 12.5% (3/24), and 12.5% (3/24) of the symptomatic patients. The "all-cause" mortality was 7.6% (5/66), with only one (1.5%) death attributable to COVID-19. Two (3%) patients required ventilation. Two (3%) patients had a delay in cancer diagnosis secondary to COVID-19 infection. Thirty-eight (57.6%) had a disruption in anticancer treatment.Conclusion Children with cancer do not appear to be at an increased risk of severe illness due to SARS-CoV-2 infection. Our findings substantiate continuing the delivery of nonintensive anticancer treatment unless sick. However, SARS-CoV-2 infection interrupted anticancer therapy in a considerable proportion of children.

7th International Conference on Communication and Electronics Systems, ICCES 2022 ; : 85-89, 2022.
Article in English | Scopus | ID: covidwho-2018796


In today's world, technology has drastically increased in all sectors of industries and businesses. Automated machines demands have increased rapidly. Most small and medium scale businesses are trying to use this technology to increase the speed and reliability. One of the booming technologies is robotics, which helps businesses in so many ways. This paper discusses the approach and experience in the design, simulation, modelling, testing, and deployment of a Low-Cost food delivery robot in hotels, restaurants etc. These food delivery robots give an enhanced experience for the customers and benefits the restaurant business financially by bringing attention to visitors and act as a publicity. The restaurant industry is also experiencing a downturn because of the COVID-19 breakout. With this method, food can be delivered directly from the kitchen to the customer's table while maintaining all norms and sanitary guidelines. The robot uses microcontroller mounted with DC motors. Ultrasonic sensors and IR sensors are used for mapping and localization of destination tables, motor drivers, obstacle detection, collision avoidance, path detection. The robot performed as per the test and achieved the desired result. © 2022 IEEE.

Asian Journal of Pharmaceutical and Clinical Research ; 14(8):108-113, 2021.
Article in English | EMBASE | ID: covidwho-1369977


Objectives: According to the recent studies, it is seen that coronavirus disease 2019 (COVID-19) infection is associated with many bacterial and fungal infections. In case of COVID-19 patients, diabetes mellitus (DM) and hypertension (HTN) are the prime risk factors and during the course of treatment, patients develop secondary fungal infections like mucormycosis. We conducted a systemic review of the present scenario and tried to evaluate the association of mucormycosis with COVID-19. Methods: We searched articles related to the COVID-19 associated mucormycosis, in PubMed, IndMed, and Cochrane Library. We conducted a meta-analysis on the basis of systemically reviewed all articles which reported COVID-19 associated with mucormycosis. We analyzed comorbidity, treatment, and outcome of patients in association with COVID-19 and mucormycosis. Results: We found a total of 196 articles based on mucormycosis, out of which only 25 were selected on the basis of our inclusion and exclusion criteria. 71 cases were found and most of the cases were from India and USA. We also found that it was more prevalent among male patients and patients with DM, and in association with HTN. Conclusion: It is seen from the studies that patients already suffering from DM and HTN when infected with coronavirus are most likely to develop mucormycosis. Treatment of latent DM, prediabetic patients, conversely, that efforts to diagnose, detect, and treat DM may have a beneficial influence in the treatment of secondary fungal infections like mucormycosis. Finding out all the cases of DM and treatment of DM can carry out an advantageous effect in all patients suffering from COVID-19.